QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
QQQ   296.28 (+0.61%)
AAPL   116.03 (+0.75%)
MSFT   213.87 (+0.00%)
FB   275.59 (-0.48%)
GOOGL   1,764.13 (+0.01%)
AMZN   3,185.07 (+2.15%)
TSLA   574.00 (+3.35%)
NVDA   529.39 (+2.14%)
BABA   277.72 (-0.80%)
CGC   26.87 (-0.37%)
GE   10.50 (+0.48%)
MU   63.43 (-0.81%)
AMD   86.71 (+1.93%)
T   28.99 (-0.82%)
NIO   53.69 (+0.34%)
F   9.08 (-3.92%)
ACB   8.71 (-5.63%)
NFLX   485.00 (+0.44%)
GILD   59.50 (-1.24%)
BA   217.61 (-0.40%)
DIS   149.09 (-1.58%)
Log in
OTCMKTS:UCBJY

UCB Stock Forecast, Price & News

$54.53
0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$54.32
Now: $54.53▼
$54.82
50-Day Range
$49.08
MA: $54.85▼
$58.51
52-Week Range
$32.45
Now: $54.53▼
$68.00
Volume5,349 shs
Average Volume14,516 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
UCB SA, a biopharmaceutical company, develops therapies and solutions for people with neurology and immunology diseases in the United States, Europe, and internationally. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; and Nayzilam, a nasal spray rescue treatment for seizure clusters. It also provides Zyrtec and Xyzal for allergies; Nootropil for memory problems; and Xyrem for narcolepsy. In addition, the company offers Evenity for the treatment of osteoporosis; bimekizumab for treating psoriasis, psoriatic arthritis, and axial spondyloarthritis; and dapirolizumab pegol for systemic lupus erythematosus. Further, it is involved in developing padsevonil for the treatment of drug-resistant epilepsy; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; UCB7858 for immunology; and UCB0599 for neurology; and UCB0107 for progressive supranuclear palsy. Additionally, the company engages in contract manufacturing activities. UCB SA has collaboration agreements with Sanofi, Amgen, Biogen, and Otsuka. The company was founded in 1928 and is headquartered in Brussels, Belgium.
Read More

Beat the Market (BTM) Rank™

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

0.52 out of 5 stars


Industry, Sector and Symbol

Stock Exchange OTCMKTS
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:UCBJY
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.ucb.com
Phone32 2 559 99 99
Employees7,600

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable
$54.53
0.00 (0.00 %)
(As of 11/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UCBJY News and Ratings via Email

Sign-up to receive the latest news and ratings for UCBJY and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











UCB (OTCMKTS:UCBJY) Frequently Asked Questions

How has UCB's stock price been impacted by Coronavirus?

UCB's stock was trading at $50.3225 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, UCBJY stock has increased by 8.4% and is now trading at $54.53.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of UCB?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for UCB in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for UCB.

What stocks does MarketBeat like better than UCB?

Wall Street analysts have given UCB a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but UCB wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting UCB?

UCB saw a increase in short interest in October. As of October 30th, there was short interest totaling 13,000 shares, an increase of 132.1% from the October 15th total of 5,600 shares. Based on an average daily volume of 21,200 shares, the short-interest ratio is currently 0.6 days.
View UCB's Short Interest.

Who are some of UCB's key competitors?

Some companies that are related to UCB include (CHV) (CHV), (DDXS) (DDXS), (PREV) (PREV), (TNGN) (TNGN), 138267 (COM.TO) (COM), 17031 (MYM), Abattis Bioceuticals (ATTBF), Abzena plc (ABZA.L) (ABZA), Acrux Limited (ACR.AX) (ACR), Actinogen Medical Limited (ACW.AX) (ACW), AdAlta Limited (1AD.AX) (1AD), ADiTx Therapeutics (ADTX), Admedus (AHZ), Alaric (HALB) and Almirall (LBTSF).
View all competitors.

Who are UCB's key executives?

UCB's management team includes the following people:
  • Mr. Jean-Christophe Tellier, CEO & Exec. Director (Age 61)
  • Dr. Dhavalkumar D. Patel, Exec. VP & Chief Scientific Officer (Age 59)
  • Mr. William J. Silbey, Exec. VP & Gen. Counsel (Age 61)
  • Mr. Jean-Luc Fleurial, Exec. VP & Chief HR Officer (Age 55)
  • Prof. Iris Löw-Friedrich, Chief Medical Officer, Head of Devel. & Medical Patient Value Practices and Exec. VP (Age 60)

What is UCB's stock symbol?

UCB trades on the OTCMKTS under the ticker symbol "UCBJY."

How do I buy shares of UCB?

Shares of UCBJY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is UCB's stock price today?

One share of UCBJY stock can currently be purchased for approximately $54.53.

What is UCB's official website?

The official website for UCB is www.ucb.com.

How can I contact UCB?

The company can be reached via phone at 32 2 559 99 99.

This page was last updated on 11/25/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.